Evelo Biosciences

$11.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.60 (-4.82%) As of 5:26 PM UTC today

Why Robinhood?

You can buy or sell EVLO and other stocks, options, and ETFs commission-free!

About EVLO

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology.

CEO
Balkrishan Gill
Employees
90
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
535.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
366.23K
High Today
$12.70
Low Today
$11.80
Open Price
$12.54
Volume
164.53K
52 Week High
$19.93
52 Week Low
$3.55

EVLO News

BenzingaApr 12

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of M

EVLO Earnings

-$0.78
-$0.52
-$0.26
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 10, Pre-Market

You May Also Like

GSEVU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure